Page last updated: 2024-12-06

4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID63062
CHEMBL ID2137046

Synonyms (24)

Synonym
SMP1_000161
BCBCMAP01_000199
smr001819827
MLS003106263
NCGC00249622-01
FT-0670138
FT-0670142
FT-0647372
S7827
HMS3370G08
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
CHEMBL2137046
AKOS028114525
phenol, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-
(e)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
BCP04749
BCP23058
Q27163871
4-hydroxytamoxifen (4-ht, afimoxifene
bdbm50276802
AMY40925
CCG-268491
FT-0670146
phenol, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized."( Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND, 2015
)
0.42
"The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described."( Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
Andrews, DM; Ballard, P; Bradbury, RH; Buttar, D; Callis, RJ; Currie, GS; Curwen, JO; Davies, CD; de Almeida, C; De Savi, C; Donald, CS; Feron, LJ; Gingell, H; Glossop, SC; Hayter, BR; Hussain, S; Karoutchi, G; Lamont, SG; MacFaul, P; Moss, TA; Norman, RA; Pearson, SE; Rabow, AA; Tonge, M; Walker, GE; Weir, HM; Wilson, Z, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase D2Homo sapiens (human)IC50 (µMol)37.02200.00611.159810.0000AID498478; AID498482
Steroid hormone receptor ERR2Homo sapiens (human)IC50 (µMol)0.76800.39501.35773.5000AID1432443; AID1499722
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.45540.00000.723732.7000AID102601; AID103082; AID103888; AID106081; AID1230134; AID1251780; AID1251781; AID1284373; AID1387887; AID1387894; AID1398797; AID1416284; AID1443551; AID1499707; AID248821; AID248974; AID249539; AID260520; AID344797; AID379024; AID70338; AID70339
Estrogen receptorHomo sapiens (human)Ki0.00120.00000.42297.9070AID239927; AID254436; AID254437; AID669588; AID68906; AID68909; AID70002; AID70347
Progesterone receptorHomo sapiens (human)IC50 (µMol)50.00040.00000.580710.0000AID1251782; AID1251783
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)Ki0.00020.00010.03040.1570AID68906
AromataseHomo sapiens (human)IC50 (µMol)530.00000.00001.290410.0000AID751071
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)9.33250.00101.979414.1600AID255211
Estrogen receptorMus musculus (house mouse)IC50 (µMol)0.03320.03326.195210.0000AID1450078
Estrogen-related receptor gammaHomo sapiens (human)IC50 (µMol)0.34850.00200.22732.0000AID1168713; AID1499723; AID260519; AID260522
Estrogen-related receptor gammaMus musculus (house mouse)IC50 (µMol)0.60000.60001.65002.7000AID1432444
Phospholipase D1 Rattus norvegicus (Norway rat)IC50 (µMol)28.00000.01100.34381.0000AID498481
Platelet-activating factor acetylhydrolaseHomo sapiens (human)IC50 (µMol)0.00050.00000.38373.9000AID103888
Phospholipase D1Homo sapiens (human)IC50 (µMol)4.80000.00101.06568.5000AID498477
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.05270.00010.529432.7000AID102601; AID103082; AID103888; AID106081; AID1284374; AID1387888; AID1387894; AID1416286; AID248821; AID248974; AID249539; AID344798; AID70030; AID70031
Estrogen receptor betaHomo sapiens (human)Ki0.00090.00000.12512.8760AID239921; AID254433; AID254435; AID68906; AID68909; AID70164; AID70658
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)EC50 (µMol)0.00820.00000.53054.4000AID1416280; AID246597; AID69862
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00600.006022.3670130.5170AID69376
Estrogen-related receptor gammaHomo sapiens (human)EC50 (µMol)0.01500.01500.66491.8990AID246440
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)0.00600.006022.3670130.5170AID69376
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)0.00080.00000.47954.8900AID246597
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)Activity0.00010.00010.00010.0001AID1356847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
phosphatidic acid biosynthetic processPhospholipase D2Homo sapiens (human)
cytoskeleton organizationPhospholipase D2Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D2Homo sapiens (human)
synaptic vesicle recyclingPhospholipase D2Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisPhospholipase D2Homo sapiens (human)
phospholipid catabolic processPhospholipase D2Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D2Homo sapiens (human)
embryonic placenta developmentSteroid hormone receptor ERR2Homo sapiens (human)
regulation of DNA-templated transcriptionSteroid hormone receptor ERR2Homo sapiens (human)
stem cell divisionSteroid hormone receptor ERR2Homo sapiens (human)
stem cell population maintenanceSteroid hormone receptor ERR2Homo sapiens (human)
cell dedifferentiationSteroid hormone receptor ERR2Homo sapiens (human)
photoreceptor cell maintenanceSteroid hormone receptor ERR2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSteroid hormone receptor ERR2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISteroid hormone receptor ERR2Homo sapiens (human)
inner ear developmentSteroid hormone receptor ERR2Homo sapiens (human)
positive regulation of stem cell population maintenanceSteroid hormone receptor ERR2Homo sapiens (human)
regulation of stem cell divisionSteroid hormone receptor ERR2Homo sapiens (human)
negative regulation of stem cell differentiationSteroid hormone receptor ERR2Homo sapiens (human)
regulation of transcription by RNA polymerase IISteroid hormone receptor ERR2Homo sapiens (human)
intracellular steroid hormone receptor signaling pathwaySteroid hormone receptor ERR2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen-related receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen-related receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayEstrogen-related receptor gammaHomo sapiens (human)
positive regulation of cold-induced thermogenesisEstrogen-related receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen-related receptor gammaHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen-related receptor gammaHomo sapiens (human)
peptide hormone processingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particle remodelingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
lipid oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
plasma lipoprotein particle oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidylcholine catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor metabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of inflammatory responsePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of monocyte chemotaxisPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidic acid biosynthetic processPhospholipase D1Homo sapiens (human)
chemotaxisPhospholipase D1Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D1Homo sapiens (human)
Ras protein signal transductionPhospholipase D1Homo sapiens (human)
cellular response to nutrientPhospholipase D1Homo sapiens (human)
regulation of microvillus assemblyPhospholipase D1Homo sapiens (human)
positive regulation of translationPhospholipase D1Homo sapiens (human)
regulation of synaptic vesicle cyclePhospholipase D1Homo sapiens (human)
phospholipid catabolic processPhospholipase D1Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (53)

Processvia Protein(s)Taxonomy
phospholipase D activityPhospholipase D2Homo sapiens (human)
protein bindingPhospholipase D2Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D2Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSteroid hormone receptor ERR2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificSteroid hormone receptor ERR2Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingSteroid hormone receptor ERR2Homo sapiens (human)
RNA polymerase II complex bindingSteroid hormone receptor ERR2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificSteroid hormone receptor ERR2Homo sapiens (human)
DNA-binding transcription factor activitySteroid hormone receptor ERR2Homo sapiens (human)
nuclear steroid receptor activitySteroid hormone receptor ERR2Homo sapiens (human)
steroid bindingSteroid hormone receptor ERR2Homo sapiens (human)
zinc ion bindingSteroid hormone receptor ERR2Homo sapiens (human)
sequence-specific DNA bindingSteroid hormone receptor ERR2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSteroid hormone receptor ERR2Homo sapiens (human)
sequence-specific double-stranded DNA bindingSteroid hormone receptor ERR2Homo sapiens (human)
estrogen response element bindingSteroid hormone receptor ERR2Homo sapiens (human)
nuclear receptor activitySteroid hormone receptor ERR2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen-related receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen-related receptor gammaHomo sapiens (human)
nuclear steroid receptor activityEstrogen-related receptor gammaHomo sapiens (human)
steroid bindingEstrogen-related receptor gammaHomo sapiens (human)
protein bindingEstrogen-related receptor gammaHomo sapiens (human)
zinc ion bindingEstrogen-related receptor gammaHomo sapiens (human)
AF-2 domain bindingEstrogen-related receptor gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen-related receptor gammaHomo sapiens (human)
estrogen response element bindingEstrogen-related receptor gammaHomo sapiens (human)
nuclear receptor activityEstrogen-related receptor gammaHomo sapiens (human)
1-alkyl-2-acetylglycerophosphocholine esterase activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipid bindingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
hydrolase activity, acting on ester bondsPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
calcium-independent phospholipase A2 activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipase D activityPhospholipase D1Homo sapiens (human)
protein bindingPhospholipase D1Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D1Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membranePhospholipase D2Homo sapiens (human)
plasma membranePhospholipase D2Homo sapiens (human)
presynapsePhospholipase D2Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D2Homo sapiens (human)
plasma membrane regionPhospholipase D2Homo sapiens (human)
integrator complexSteroid hormone receptor ERR2Homo sapiens (human)
condensed chromosomeSteroid hormone receptor ERR2Homo sapiens (human)
nucleusSteroid hormone receptor ERR2Homo sapiens (human)
nucleoplasmSteroid hormone receptor ERR2Homo sapiens (human)
cytoplasmSteroid hormone receptor ERR2Homo sapiens (human)
cytosolSteroid hormone receptor ERR2Homo sapiens (human)
chromatinSteroid hormone receptor ERR2Homo sapiens (human)
nucleusSteroid hormone receptor ERR2Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
nucleoplasmEstrogen-related receptor gammaHomo sapiens (human)
chromatinEstrogen-related receptor gammaHomo sapiens (human)
nucleusEstrogen-related receptor gammaHomo sapiens (human)
extracellular regionPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
high-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
cholinergic synapsePhospholipase D1Homo sapiens (human)
Golgi membranePhospholipase D1Homo sapiens (human)
lysosomal membranePhospholipase D1Homo sapiens (human)
endosomePhospholipase D1Homo sapiens (human)
endoplasmic reticulum membranePhospholipase D1Homo sapiens (human)
Golgi apparatusPhospholipase D1Homo sapiens (human)
plasma membranePhospholipase D1Homo sapiens (human)
membranePhospholipase D1Homo sapiens (human)
apical plasma membranePhospholipase D1Homo sapiens (human)
endocytic vesiclePhospholipase D1Homo sapiens (human)
late endosome membranePhospholipase D1Homo sapiens (human)
specific granule membranePhospholipase D1Homo sapiens (human)
perinuclear region of cytoplasmPhospholipase D1Homo sapiens (human)
tertiary granule membranePhospholipase D1Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D1Homo sapiens (human)
plasma membrane regionPhospholipase D1Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (298)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1398802Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID70030Inhibitory concentration against estrogen receptor 2 using estrogen response element (ERE) assay.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID42280Percent of inhibitory activity against proliferation of BT-20 cells in presence of TPE at 10e-5 M concentration.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID251180Antagonist effect against 10 pM 17-beta-estradiol induced MCF-7 cell proliferation2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID70164In vitro displacement of 0.5 nM [3H]17-beta-estradiol from human Estrogen receptor beta2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.
AID1228241Induction of estrogen receptor-alpha degradation in human MCF7 cells at 1 uM after 20 hrs by Western blot analysis2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
AID673837Cytotoxicity against human MDA-MB-231 cells assessed as cell survival at 10'-7 M relative to vehicle-treated control2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID70502Binding affinity against estrogen receptor alpha relative to E22004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
AID251181Inhibition of 1 nM 17-beta- estradiol stimulated alkaline phosphatase induction in Ishikawa endometrial cells2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID344791Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
AID498478Inhibition of GFP-tagged human PLD2 expressed in human HEK293 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1480300Selectivity index, ratio of cytotoxic activity for human HeLa cells to IC50 for Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID1398805Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID102415Effect of compound on the growth of MCF-7 cells at a concentration of 10 e-7 M Experiment 2, percentage of control value being 151985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID1152712Agonist activity at ER in human MCF7:WS8 cells assessed as pS2 gene expression at 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID248821Antagonist effect against 10 pM 17-beta-estradiol induced MCF-7 cell proliferation2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID232815Partial agonist/antagonist effect on transcriptional activation by human ER alpha and ER beta on vitellogenin A2 ERE2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.
AID344797Displacement of fluorescein labeled estradiol from human recombinant ERalpha expressed in baculovirus infected insect cells by fluorescence polarization assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
AID70006Relative binding affinity for Estrogen receptor alpha compared to estradiol2003Bioorganic & medicinal chemistry letters, Apr-17, Volume: 13, Issue:8
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain.
AID711885Antiproliferative activity against human MCF7 cells assessed as incorporation of [methyl-3H]thymidine into cellular DNA in serum free medium in in presence of 6.2 ug/mL RNase 12012ACS medicinal chemistry letters, Feb-28, Volume: 3, Issue:4
Ribonuclease-Activated Cancer Prodrug.
AID620850Binding affinity to bovine serum albumin at pH 7.4 by fluorescence spectroscopy2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID251179Agonist activity as efficacy in alkaline phosphatase induction in Ishikawa endometrial cells compared to E22004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID1453276Antiproliferative activity against human MDA-MB-453 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Dual functional small molecule fluorescent probes for image-guided estrogen receptor-specific targeting coupled potent antiproliferative potency for breast cancer therapy.
AID1398797Antagonist activity at recombinant human ERalpha expressed in HEK293 cells assessed as inhibition of estradiol-induced YFP-fused SRC1 coactivator recruitment measured after 1 hr in presence of Coelenterazine H by BRET assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1284372Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Apr-13, Volume: 112Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
AID498481Inhibition of N-terminally truncated rat PLD1 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID254437Binding affinity towards human estrogen receptor alpha in a competitive binding assay using fluorescently labelled estradiol2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID1156322Anticancer against human ER-positive MCF7 cells assessed as cell viability after 48 hrs by SRB assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID620852Effect on secondary structure of bovine serum albumin assessed as beta-sheet content at 0.5 uM at pH 7.4 by circular dichroism method (Rvb = 16 %)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID70002In vitro displacement of 0.5 nM [3H]17-beta-estradiol from human Estrogen receptor alpha2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.
AID1443552Induction of ERalpha degradation in human MCF7 cells assessed as remaining ERalpha protein level at 10 uM after 18 to 24 hrs by Western blot analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
AID1416290Inverse agonist activity at ERbeta (unknown origin) expressed in HEK293T cells assessed as inhibition of transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to 17beta-estradiol2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID69386Percent inhibition of [3H]estradiol binding to cytoplasmic estrogen receptor of rat uterus1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID673829Cytotoxicity against human T47D cells after 5 days2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID1443551Antagonist activity at ERalpha in human MCF7 cells assessed as inhibition of estrogen-induced transcription preincubated overnight followed by estrogen addition measured after 24 hrs by dual luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
AID597271Antiproliferative activity against human MCF7 cells expressing estrogen receptor incubated with 100 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID102601Inhibition of estradiol-stimulated MCF-7 breast adenocarcinoma cell proliferation2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
AID1356847Induction of ERalpha degradation in human MCF7 cells in phenol red free RPMI medium containing 5% charcoal dextran-treated FBS incubated for 4 hrs by SP1 and anti-ER rabbit monocolnal antibody based in-cell Western assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
AID103376Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID700064Antagonist activity at ERalpha co-activator binding domain expressed in human HepG2 cells assessed as inhibition of E2-induced GR1P1 LXXLL2 binding measured as decrease in beta-galactosidase activity at <20 uM after 40 hrs by luciferase reporter gene assa2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding.
AID597270Antiproliferative activity against human MCF7 cells expressing estrogen receptor incubated with 0.003 nM of estradiol and 0.01 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of 5% fetal bovine serum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID176789In vivo inhibition of estrogen-stimulated uterine weight gain in immature rats on peroral administration; ND=not determined1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
AID1230134Inhibition of ERalpha (unknown origin) by fluorescence polarization-based competition binding assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
AID711887Antiproliferative activity against human MCF7 cells assessed as incorporation of [methyl-3H]thymidine into cellular DNA in serum free medium in in absence of 6.2 ug/mL RNase 12012ACS medicinal chemistry letters, Feb-28, Volume: 3, Issue:4
Ribonuclease-Activated Cancer Prodrug.
AID69056In vitro relative binding affinity by competition with [3H]17-beta-estradiol for estrogen receptor in MCF-7 cell lysate1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1152714Agonist activity at ER in human MCF7:WS8 cells assessed as increase in PgR gene expression at 10'-6 M after 48 hrs by RT-PCR analysis relative to control2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID239927Binding affinity for human estrogen receptor alpha2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
AID1233267Antiproliferative activity against african green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTT assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID1398820Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of MKI67 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID597267Antiproliferative activity against human MCF7 cells expressing estrogen receptor incubated with 0.06 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID756455Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of novel tamoxifen analogues.
AID1499722Antagonist activity at recombinant GST-tagged human ERRbeta LBD assessed as inhibition of fluorescein-labeled coactivator peptide recruitment preincubated with enzyme followed by coactivator addition by LanthaScreen TR-FRET assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
AID673824Growth inhibition of human MCF7 cells at 10'-7 M after 5 days relative to control2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID658133Antiproliferative activity against human MCF7 cells2012European journal of medicinal chemistry, May, Volume: 51Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
AID102422Effect of compound with 10e-8 M estradiol on the growth of MCF-7 cells at a concentration 10 e-7 M, percentage of control value being 851985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID1416287Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID1152713Agonist activity at ER in human MCF7:WS8 cells assessed as GREB1 gene expression at 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID392054Antiproliferative activity against human MCF7 cells at 0.625 nM after 24 hrs by MTS assay2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer.
AID102768Percent of effective dose for [3H]estradiol against proliferation of MCF-7 cells.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID239828Relative binding affinity for Estrogen receptor beta2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
AID1398812Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of MYC mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID344794Antiproliferative activity against hormone independent human MDA-MB-231 cells upto 100 nM after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
AID106081Anti-estrogenicity for 50% inhibition of the MVLN cell luciferase activity due to 0.1 nM E2 (estradiol)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes.
AID1443610Induction of ERalpha degradation in human MCF7 cells after 18 hrs by Western blot analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
AID69837Relative binding affinity to the estrogen receptor in lamb uterus cytosol1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID103888Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1387887Displacement of fluorescein-labeled estradiol (fluoromone) from human recombinant full-length estrogen receptor alpha after 2 hrs by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID1480302Binding affinity to Ebolavirus glycoprotein/matrix protein VP40 at 50 uM incubated for 10 mins by thermal shift assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID68906Inhibition of estradiol binding to estrogen receptor in Human Breast cancer cytosol (3.3% ethanol)1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
AID1251784Antiproliferative activity against human MCF7 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
AID1398817Inhibition of HDAC6/HDAC3 in human MCF7 cells assessed as induction of CTGF mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1398821Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of CCND1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1156321Anticancer against human ER-positive MCF7L cells assessed as cell viability after 48 hrs by SRB assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID103559Cytostaticity against MCF-7 cells in the presence of 1 uMolar E2 (estradiol)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes.
AID103897Antiproliferative activity against MCF-7 cell line2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
AID71116Inhibition of [3H]estradiol binding to calf uterine Estrogen receptor relative to tamoxifen1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
AID1398822Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of MYBL2 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1416284Antagonist activity at ERalpha (unknown origin) expressed in HEK293T cells assessed as inhibition of 17beta-estradiol stimulated transcriptional activity after 24 hrs by dual luciferase reporter gene assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1450078Antagonist activity at estrogen receptor in mouse GT1-7 cells harboring beta-galactosidase reporter gene assessed as reduction in 17beta-estradiol induced response measured after 20 to 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Efficient synthesis of a multi-substituted diphenylmethane skeleton as a steroid mimetic.
AID473402Estrogenic activity in human ERalpha expressing MCF7:WS8 cells assessed as stimulation of cell proliferation after 7 days2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID69376In vitro displacement of 3 nM [3H]4-hydroxytamoxifen from estrogen receptor of rat uterine cystol1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and estrogen receptor selectivity of 1,1-bis(4-hydroxyphenyl)-2-(p-halophenyl)ethylenes.
AID239921Binding affinity for human estrogen receptor beta2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
AID1416283Antagonist activity at ERalpha (unknown origin) expressed in HEK293T cells assessed as inhibition of 17beta-estradiol stimulated transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to 17beta-estradiol2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID1156341Resistance index, ratio of IC50 for human SKOV3-MDR1-M6/6 cells to IC50 for human SKOV3 cells2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID251175Estrogen-Related Receptor gamma activity in FRET assay2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.
AID249539pIC50 for 1 nM estradiol-induced Ishikawa cell proliferation2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
AID1209448Activity at CYP2B6 (unknown origin) expressed Escherichia coli C41 DE3 cells assessed as enzyme-mediated 4-hydroxytamoxifen quinone methide metabolite formation by measuring reactive metabolite adduct with GSHEE at 90 uM by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein.
AID102623Percent of inhibitory activity against proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]estradiol (E2).1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID105943Estrogenicity of compound for maximal induction of MVLN cell luciferase activity in the absence of E2 (estradiol).1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes.
AID237575Octanol-water partition coefficient (logP) of the compound measured by RP-HPLC2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
AID103600Agonistic activity in MCF-7 cell proliferation.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID1416286Antagonist activity at ERbeta (unknown origin) expressed in HEK293T cells assessed as inhibition of 17beta-estradiol stimulated transcriptional activity after 24 hrs by dual luciferase reporter gene assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID1387881Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID514397Cytostatic activity against human MCF7 cells at 10 uM after 3 days by microtiter assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
AID620851Effect on secondary structure of bovine serum albumin assessed as beta antiparallel content at 0.5 uM at pH 7.4 by circular dichroism method (Rvb = 3 %)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID246597Agonist activity as alkaline phosphatase induction in Ishikawa endometrial cells compared to E22004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID260522Inhibition of interaction between ERRgamma and NR cofactor RIP140 in FRET assay2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID1156323Anticancer against human ER-negative AU565 cells assessed as cell viability after 48 hrs by SRB assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID214256Ability to inhibit release of interleukin-6 from U2OS cell lines transfected with estrogen receptor alpha2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
AID597272Antiproliferative activity against estrogen receptor-deficient human MCF12A cells incubated with 0.003 nM of estradiol and 0.01 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of 5% fetal bovine serum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID1398803Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID254435Binding affinity towards human estrogen receptor beta in a competitive binding assay using fluorescently labelled estradiol2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID1191565Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Structure-activity relationship study of diphenylamine-based estrogen receptor (ER) antagonists.
AID1233268Therapeutic index, ratio of IC50 for african green monkey Vero cells to IC50 for human MCF7 cells2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1156327Anticancer against human SKOV3-MDR1-M6/6 cells assessed as cell viability after 48 hrs by SRB assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID1499723Antagonist activity at ERRgamma (unknown origin) assessed as inhibition of co-activator peptide recruitment by TR-FRET assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID669590Selectivity ratio of Ki for ERbeta to Ki for ERalpha2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
AID1284373Displacement of [3H]-E2 from human ER-alpha incubated for 16 to 20 hrs by liquid scintillation counting analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
AID1156324Anticancer against human ER-positive MCF7 cells assessed as inhibition of estradiol-induced cell proliferation after 3 days2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID1453274Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Dual functional small molecule fluorescent probes for image-guided estrogen receptor-specific targeting coupled potent antiproliferative potency for breast cancer therapy.
AID597274Antiproliferative activity against estrogen receptor-deficient human MCF12A cells incubated with 100 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID1416280Agonist activity at ERalpha (unknown origin) expressed in HEK293T cells assessed as transcriptional activity after 24 hrs by dual luciferase reporter gene assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID392053Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer.
AID1398810Inhibition of HDAC6 in human MCF7 cells assessed as increase in acetylated alpha-tubulin expression at 0.1 to 9 uM after 8 hrs by Western blot analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1356848Induction of ERalpha degradation in human MCF7 cells in phenol red free RPMI medium containing 5% charcoal dextran-treated FBS incubated for 4 hrs by SP1 and anti-ER rabbit monocolnal antibody based in-cell Western assay relative to fulvestrant2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
AID1251783Antagonist activity at progesterone receptor in human MCF cells assessed as estradiol-induced receptor response2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
AID1152696Agonist activity at ER in human MCF7:WS8 cells assessed as cell growth by measuring DNA level at 10'-12 to 10'-6 M after 7 days by fluorescence analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID1398816Inhibition of HDAC6/HDAC3 in human MCF7 cells assessed as induction of SREBF1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID103082Inhibition of estradiol induced estrogen receptor transcriptional activation in MCF-7-2a cells2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
AID756454Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of novel tamoxifen analogues.
AID248974Antagonist activity as inhibition of 1 nM 17-beta-estradiol stimulated alkaline phosphatase induction in Ishikawa endometrial cells2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID1156319Anticancer against human SKOV3 cells overexpressing P-gp assessed as cell viability after 48 hrs by SRB assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID673830Ratio of tamoxifen IC50 to compound IC50 for human MCF7 cells2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID102412Effect of compound on the growth of MCF-7 cells at a concentration of 10 e-6 M Experiment 2, percentage of control value being 131985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID597269Antiproliferative activity against estrogen receptor-deficient human NCI-ADR-RES cells incubated with 0.06 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID164971Percent stimulation or inhibition of protein kinase C III activity for phosphatidylserine (PS) in the presence of [Ca2+].1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID681359TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells1994Biochemical pharmacology, Jul-19, Volume: 48, Issue:2
Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.
AID1251781Antagonist activity at ERalpha receptor in human MCF7 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
AID1152705Antagonist activity at ER in rat GH3 cells assessed as inhibition of estradiol-induced prolactin gene expression at 10'-10 to 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID1284375Selectivity ratio of IC50 for human ER-alpha to IC50 for human ER-beta2016European journal of medicinal chemistry, Apr-13, Volume: 112Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
AID514395Cytostatic activity against human MCF7 cells at 5 uM after 3 days by microtiter assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
AID1230135Inhibition of ERalpha (unknown origin) by fluorescence polarization-based competition binding assay relative to E22015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
AID1152704Antagonist activity at ER in rat GH3 cells assessed as inhibition of estradiol-induced prolactin gene expression at 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID673836Drug uptake in human MCF7 cells at 10'-6 M after 6 days by HPLC-MS/MS analysis2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID597276Antiproliferative activity against androgen receptor-deficient human DU145 cells incubated with 0.6 nM of estradiol and 0.7 nM of testosterone after 48 hrs by sulforhodamine B assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID1432444Inverse agonist activity at GAL4-DNA binding domain-fused mouse ERRgamma ligand binding domain expressed in African green monkey CV1 cells assessed as decrease in receptor transcriptional activity after 45 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID597268Antiproliferative activity against estrogen receptor-deficient human NCI-ADR-RES cells incubated with 100 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID71122Relative binding affinity against estrogen receptors in calf uterine cytosol.1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.
AID260519Displacement of [3H]4-OHT from ERRgamma2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID170810Anti-uterotrophic effect in rats at 50 ug/animal/day in the presence of 0.5 ug estradiol benzoate1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID103380Percent agonistic activity in MCF-7 breast tumor cells using MCF-7 assay2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID191709Uterotrophic effect in rats at 50 ug/animal/day hydroxytamoxifen1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID102413Effect of compound on the growth of MCF-7 cells at a concentration of 10 e-6 M, percentage of control value being 231985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID70658Binding affinity for estrogen receptor beta2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
AID1230131Reduction in endogenous ERalpha expression in human MCF7 cells at 10 uM after 6 hrs by Western blot analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
AID1398823Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of CDC6 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID102602In vitro inhibition of MCF-7 cell proliferation compared to 0.1 nM [3H]-estradiol.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID68909Apparent inhibition constant for estrogen receptor in Human uterine cytosol in 3.3%ethanol1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
AID1398804Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1152703Agonist activity at ER in rat GH3 cells assessed as increase in prolactin mRNA level at 10'-13 to 10'-6 M after 48 hrs by RT-PCR analysis relative to estradiol2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID673826Growth inhibition of human T47D cells at 10'-7 M after 5 days relative to control2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID673825Growth inhibition of human MCF7 cells at 10'-6 M after 5 days relative to control2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID102435Effective dose for [3H]- estradiol against proliferation of MCF-7 cells1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1058078Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Amino acids derived benzoxazepines: design, synthesis and antitumor activity.
AID1443577Induction of ERalpha degradation in human MCF7 cells assessed as inhibition of insulin-mediated cell proliferation after 6 days by Hoechst 33258 dye-based assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
AID260521Selectivity for ERRgamma over ERalpha relative to 4-hydroxytamoxifen2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID473404Antiestrogenic activity in human MCF7 cells assessed as inhibition of estradiol-stimulated prolactin gene expression2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID69370Specific binding to estrogen receptor in rat uterine cytosol(+/-SD)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and estrogen receptor selectivity of 1,1-bis(4-hydroxyphenyl)-2-(p-halophenyl)ethylenes.
AID69520Receptor binding affinity(RBA) for rat uterine cytosolic estrogen receptor relative to estradiol1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Rationally designed analogues of tamoxifen with improved calmodulin antagonism.
AID1387888Displacement of fluorescein-labeled estradiol (fluoromone) from human recombinant full-length estrogen receptor beta after 2 hrs by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID657937Relative binding affinity to estrogen receptor2012European journal of medicinal chemistry, May, Volume: 51Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
AID239820Mean fluorescence intensity corrected to basal for GW-5638 selective peptide binding to human estrogen receptor alpha2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
AID69062Relative binding affinity of Estrogen receptor measured by using [3H]17-beta-estradiol1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID679347TP_TRANSPORTER: transepithelial transport in Caco-2 cells2004Biopharmaceutics & drug disposition, Oct, Volume: 25, Issue:7
Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.
AID70031Inhibitory concentration against estrogen receptor 2 using radioligand binding assay.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID239829Relative binding affinity for Estrogen receptor alpha2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
AID673828Cytotoxicity against human MCF7 cells after 5 days2012ACS medicinal chemistry letters, Apr-06, Volume: 3, Issue:5
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
AID1152716Effect on ER-alpha protein level in human MCF7:WS8 cells after 24 hrs by Western blot analysis relative to control2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID176791In vivo inhibition of estrogen-stimulated uterine weight gain in immature rats on subcutaneous administration; ND=not determined1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
AID1398813Antagonist activity at ESR1 in human MCF7 cells assessed as suppression of ESR1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID244507Ishikawa cell alkaline phosphatase activity as percent maximal induction relative to 17 alpha-estradiol2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
AID69068Relative affinity for estrogen receptor of Human Breast cancer or normal uterine cytosol (3.3%ethanol) compared to estradiol1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1233266Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTT assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID344798Displacement of fluorescein labeled estradiol from human recombinant ERbeta expressed in baculovirus infected insect cells by fluorescence polarization assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
AID597273Antiproliferative activity against estrogen receptor-deficient human MCF12A cells incubated with 0.06 nM of estradiol and 0.07 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of fetal bovine serum and NuSerum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID597277Antiproliferative activity against human LNCAP cells expressing androgen receptor incubated with 0.6 nM of estradiol and 0.7 nM of testosterone after 48 hrs by sulforhodamine B assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID1387891Selectivity index, ratio of IC50 for human recombinant full-length estrogen receptor beta to IC50 for human recombinant full-length estrogen receptor alpha2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID69368Non specific binding to estrogen receptor in rat uterine cytosol(+/-SD)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and estrogen receptor selectivity of 1,1-bis(4-hydroxyphenyl)-2-(p-halophenyl)ethylenes.
AID1192746Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID102593Inhibition of estrogen-stimulated MCF-7 cell proliferation1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1387882Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 10 uM by CytoTox 96 non-radioactive LDH cytotoxicity assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID102624Percent of inhibitory activity versus 0.1 nm [3H]estradiol against proliferation of MCF-7 cells.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1398806Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID238874Inhibition of [3H]estradiol binding to Estrogen receptor beta2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID103083Inhibition of MCF-7 cell proliferation at 5 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
AID1284374Displacement of [3H]-E2 from human ER-beta incubated for 16 to 20 hrs by liquid scintillation counting analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
AID473406Estrogenic activity at wild type ER alpha expressed in T47D:C:4:2 cells coexpressing estrogen response element by duel luciferase reporter gene assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID103080Agonistic effect on estrogen receptor mediated transcriptional activation in MCF-7-2a cells at 1 uM compared to 10e-8 M estradiol2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
AID1251780Binding affinity to ERalpha receptor (unknown origin)2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
AID473403Antiestrogenic activity in human ERalpha expressing MCF7:WS8 cells assessed as inhibition of estradiol-induced proliferation at 1 uM after 7 days2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1432443Inverse agonist activity at GAL4-DNA binding domain-fused human ERRbeta ligand binding domain expressed in African green monkey CV1 cells assessed as decrease in receptor transcriptional activity after 45 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID620853Effect on secondary structure of bovine serum albumin assessed as turn structure content at 0.5 uM at pH 7.4 by circular dichroism method (Rvb = 12 %)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID225255Inhibition of calmodulin-dependent Phosphodiesterase1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Rationally designed analogues of tamoxifen with improved calmodulin antagonism.
AID70339Inhibitory concentration against estrogen receptor alpha using radioligand binding assay.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID38612Relative binding affinity for antiestrogen binding site (AEBS) of calf uterus 2 hr incubation at 0C1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1499707Inhibition of fluormone ES2 green binding to recombinant full length human ERalpha expressed in insect cells by fluorescence polarization assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
AID238886Inhibition of [3H]estradiol binding to Estrogen receptor alpha2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Benzothiophene and naphthalene derived constrained SERMs.
AID1398819Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of E2F1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1432442Inverse agonist activity at GAL4-DNA binding domain-fused human ERRalpha ligand binding domain expressed in African green monkey CV1 cells assessed as decrease in receptor transcriptional activity at 10 uM after 45 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID254433Antagonistic activity against estrogen receptor beta in presence of 0.1 nM estradiol2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID473405Antiestrogenic activity in human MCF7 cells assessed as inhibition of estradiol-stimulated proliferation2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID69862Binding affinity for Estrogen receptor alpha2003Bioorganic & medicinal chemistry letters, Apr-17, Volume: 13, Issue:8
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain.
AID71114Inhibition of [3H]estradiol binding to Estrogen receptor of MCF-7 cell lysate relative to tamoxifen1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
AID669588Displacement of [3H]estradiol from ERalpha after 4 hrs by scintillation counting2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
AID1387898Displacement of fluorescein-labeled estradiol (fluoromone) from human recombinant full-length estrogen receptor beta after 2 hrs by fluorescence polarization assay relative to estradiol2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID756453Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of novel tamoxifen analogues.
AID246440Estrogen-Related Receptor gamma activity in FRET assay2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.
AID344801Selectivity ratio of IC50 for human recombinant ERalpha to IC50 for human recombinant ERbeta2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
AID1416289Inverse agonist activity at ERbeta (unknown origin) expressed in HEK293T cells assessed as transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to 17beta-estradiol2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID700067Agonist activity at ERalpha co-activator binding domain expressed in human HepG2 cells assessed as GRP1P1 LXXLL2 binding measured as beta-galactosidase activity after 40 hrs by luciferase reporter gene assay relative to control2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding.
AID1233265Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID70338Inhibitory concentration against estrogen receptor alpha using estrogen response element (ERE) assay.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID103267Inhibition of estrogen-induced proliferation in human MCF-7 breast cancer cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
AID620854Effect on secondary structure of bovine serum albumin assessed as random coil content at 0.5 uM at pH 7.4 by circular dichroism method (Rvb = 6 %)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID1398814Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of GREB1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID102448Inhibitory activity against proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]- estradiol (E2)1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1168713Agonist activity at human estrogen related receptor gamma expressed in HEK293 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID1416279Agonist activity at ERalpha (unknown origin) expressed in HEK293T cells assessed as transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to 17beta-estradiol2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
AID392055Antiproliferative activity against human MCF7 cells at >0.625 to 10 nM after 24 hrs by MTS assay2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer.
AID71132Relative binding affinity was measured on calf uterus estrogen receptor after 5 hr at 25C.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID102428Effect on the growth of MCF-7 cells at a concentration of 10 e-7 M, percentage of control value being 361985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID103428Cytotoxicity against MCF-7 cells in presence of 1 uM E2 (estradiol)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes.
AID103754Cytostatic activity against MCF-7 cell proliferation.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID103427Cytotoxicity against MCF-7 cells in the absence of 1 uM E2 (estradiol)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes.
AID102424Effect of compound with 10e-8 M estradiol on the growth of MCF-7 cells at a concentration of 10 e-6 M, percentage of control value being 321985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID260520Displacement of [3H]estradiol from ERalpha2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID70180Displacement of [3H]E2 from calf uterine estrogen receptor2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID498477Inhibition of PLD1 in human Calu-1 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID70347Binding affinity for estrogen receptor alpha2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
AID1156320Anticancer against human ER-positive MDA-MB-231 cells assessed as cell viability after 48 hrs by SRB assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID499833Antiestrogenic activity in human MCF7 cells assessed as decrease of ER-mediated PR expression at 100 uM by RT-PCR analysis in presence of estradiol2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID620848Effect on secondary structure of bovine serum albumin assessed as alpha-helix content at 0.5 uM at pH 7.4 by circular dichroism method (Rvb = 63 %)2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID498480Stimulation of human PLD1 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID103375Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID1192744Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID1453275Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Dual functional small molecule fluorescent probes for image-guided estrogen receptor-specific targeting coupled potent antiproliferative potency for breast cancer therapy.
AID254436Antagonistic activity against estrogen receptor alpha in presence of 0.1 nM estradiol2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID164970The percent stimulation or inhibition of protein kinase C III activity was determined for phosphatidylserine (PS) and diolein(PS+DO) in the presence of [Ca2+]1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID71134Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 5 hours at 25 degree Centigrade.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1443550Displacement of [3H]-estradiol from recombinant human N-terminal His-tagged ERalpha LBD harboring C381S/C417S/C530S mutant expressed in Rosetta 2 DE3 competent cells after 1 hr by SPA binding assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
AID620856Binding affinity to bovine serum albumin at pH 7.4 by McGhee and von Hippel method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID379024Antiestrogenic activity at estrogen receptor alpha expressed in yeast cells assessed as inhibition of 17-beta-estradiol-induced beta-galactosidase activity by two hybrid assay2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids with antiestrogenic activity from Millettia pachycarpa.
AID235276Ratio of specific binding to non-specific binding at rat estrogen receptor1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and estrogen receptor selectivity of 1,1-bis(4-hydroxyphenyl)-2-(p-halophenyl)ethylenes.
AID1398801Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID751071Inhibition of human recombinant placental aromatase2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
AID103394Growth inhibitory activity against MCF-7 human breast tumor cell line at a concentration of 10e-8 M in vitro.1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.
AID1398818Inhibition of HDAC6/HDAC3 in human MCF7 cells assessed as induction of CDKN1A mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID104076In vitro cytotoxicity against hormone-responsive MCF-7 cell line.1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Rationally designed analogues of tamoxifen with improved calmodulin antagonism.
AID1480299Selectivity index, ratio of cytotoxic activity for HEK293 cells to IC50 for Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID103392Growth inhibitory activity against MCF-7 human breast tumor cell line at a concentration of 10e-6 M in vitro.1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.
AID514396Cytostatic activity against human MDA-MB-231 cells after 3 days by microtiter assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
AID1058077Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Amino acids derived benzoxazepines: design, synthesis and antitumor activity.
AID620855Binding affinity to bovine serum albumin at pH 7.4 by Stern-Volmer plot2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
AID473407Estrogenic activity at wild type ER alpha D351G mutant expressed in T47D:C:4:2 cells coexpressing estrogen response element by duel luciferase reporter gene assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1061857Binding affinity to ERalpha (unknown origin) relative to tamoxifen2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator.
AID1251782Agonist activity at progesterone receptor in human MCF7 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
AID38611Relative binding affinity for antiestrogen binding site (AEBS) of calf uterus cytosol1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID597266Antiproliferative activity against estrogen receptor-deficient human NCI-ADR-RES cells incubated with 0.003 nM of estradiol and 0.01 nM of testosterone after 48 hrs by sulforhodamine B assay in presence of 5% fetal bovine serum2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID498482Inhibition of human PLD2 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID503066Displacement of E2-Alexa633 from GFP-tagged ERalpha expressed in COS7 cells by FACS2006Nature chemical biology, Apr, Volume: 2, Issue:4
Virtual and biomolecular screening converge on a selective agonist for GPR30.
AID103393Growth inhibitory activity against MCF-7 human breast tumor cell line at a concentration of 10e-7 M in vitro.1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.
AID473401Activation of human ER in human MCF7:WS8 cells expressing estrogen responsive element by luciferase reporter gene assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1156326Anticancer against human ER-positive MCF7 cells assessed as inhibition of estradiol-induced cell proliferation at 250 to 500 nM after 5 days2014European journal of medicinal chemistry, Jul-23, Volume: 82Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents.
AID1061856Upregulation of ERalpha protein levels in human MCF7 cells at 10 uM after 6 hrs by Western blot method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator.
AID1387894Antagonist activity at estrogen receptor alpha/beta in human Ishikawa cells after 72 hrs by alkaline phosphatase assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID220010Inhibition of calmodulin dependent cAMP phosphodiesterase.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin.
AID1398809Inhibition of HDAC3 in human MCF7 cells assessed as increase in acetylated histone H4 expression at 0.1 to 9 uM after 8 hrs by Western blot analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID164972Percent stimulation or inhibition of protein kinase C III activity for protamine sulfate in the presence of EGTA.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID71133Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 2 hours at 0 degree Centigrade.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1387892Displacement of fluorescein-labeled estradiol (fluoromone) from human recombinant full-length estrogen receptor alpha after 2 hrs by fluorescence polarization assay relative to estradiol2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
AID234090Selectivity for relative binding affinity against estrogen receptor at 2 hrs and 5 hr in calf uterus cytosol1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1398815Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of TFF1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID42278Inhibitory activity against proliferation of BT-20 cells in presence of TPE at 10e-5 M concentration.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1192745Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
AID597275Antiproliferative activity against androgen receptor-deficient human PC3 cells incubated with 0.6 nM of estradiol and 0.7 nM of testosterone after 48 hrs by sulforhodamine B assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
AID493017Wombat Data for BeliefDocking2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (7.89)18.7374
1990's9 (11.84)18.2507
2000's22 (28.95)29.6817
2010's38 (50.00)24.3611
2020's1 (1.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.53 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (97.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]